28
Participants
Start Date
March 10, 2021
Primary Completion Date
September 30, 2028
Study Completion Date
September 30, 2028
UCART19 follow-up
UCART19 will not be administered during the study period. Patients who will be rolled-over from the parent study to this long term follow-up study, have previously received UCART19. The roll-over occurs at the end of the parent study, or at any time after UCART19 administration, in case of premature discontinuation from the parent study.
Children's Hospital of Philadelphia, Philadelphia
Moffit Cancer Center, Tampa
Hôpital Saint-Louis, Paris
Hôpital Robert-Debré, Paris
University of Texas Southwestern Medical Center, Dallas
Hôpital Saint-Antoine, Paris
University of Texas MD Anderson Cancer Center, Houston
Colorado Blood Cancer Institute, Denver
Children's Hospital Los Angeles, Los Angeles
Massachussetts General Hospital, Charlestown
Kyushyu University Hospital, Fukuoka
Hokkaido University Hospital, Sapporo
Hospital San Juan De Dios, Barcelona
King's College Hospital NHS Foundation Trust, London
UCL Great Ormond Hospital, London
The Christie NHS Foundation Trust, Manchester
ADIR, a Servier Group company
INDUSTRY
Institut de Recherches Internationales Servier
OTHER